CVS Crushes Q1 By 17%, Raises 2026 Guide $5B As Insurance Limb Goes Full-Send…

By Stocks News   |   6 months ago   |   Stock Market News
CVS Crushes Q1 By 17%, Raises 2026 Guide $5B As Insurance Limb Goes Full-Send…

Aetna-thin’ but a peanut… 

The insurance limb that almost killed CVS just printed the fourth (or fifth… Brian Newman lost count) straight beat-and-raise. Q1 EPS landed at $2.57 adjusted against the Street's $2.20, a 17% beat. Revenue ripped to $100.43 billion versus the $95.09 billion expected. Aaaaand just like that the stock ripped 7%. Bigly. 

As for the money shot, it was all Aetna. The unit that spent two years bleeding the parent dry just dropped its medical benefit ratio 270 basis points to 84.6%, a number so much better than the 86.3% analysts were modeling that you could basically see the shorts soiling themselves. Translation: Lower MBR = the insurer keeps more of the premium, less of it walks out the door as actual healthcare. Aetna is officially keeping more of your money.

Which means CVS now sees full-year EPS at $7.30 to $7.50, up from $7.00 to $7.20, and full-year revenue of "at least" $405 billion (up five fat billion from the prior outlook, just so we're clear who lifted whom). Newman attributed the bulk of the raise to "tailwinds" at Aetna. 

Additionally, pharmacy retail came in at $31.99 billion, basically flat year-over-year. In the year of our lord 2026, flat is a win for a brick-and-mortar drug store getting circled by Amazon and Mark Cuban's Cost Plus side project. Case in point: In Newman’s own words he’s “happy we’re not getting a lot of surprises”.

Over on the Caremark side… a.k.a., the PBM that decides which meds your insurance won’t will cover and at what markup, posted $48.24 billion in revenue, up 11%. (Friendly reminder, PBM’s are the middlemen who can kill your prescription before it kills you.) That's the third leg of the CVS conglomerate, growing double digits while every analyst note in the building stays fixated on Aetna. Caremark is the ATM in the back room nobody's writing about.

Meanwhile, in Minnetonka, Stephen Hemsley is twelve months into his own UNH turnaround attempt, the one UnitedHealth promised investors when they yanked him out of retirement last May. Medical costs at UNH still aren't falling. Newman's "we're not getting surprises" lands different when your biggest competitor is getting nothing BUT f*cking surprises. Three points for Brian. 

In the end, confidence is back with a prudent view on costs, while medical inflation is “still too high”. Put another way, CVS is gonna take another lap on the beat-and-raise treadmill and let everyone else explain why their MBRs look like ZIP codes. Regardless, the limb has fully reattached, the body is walking, and CVS, against all odds, is… healed. (For now). Until next time, friends… 

 

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article. 

 

Did you find this insightful?

Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer